The New York Times, the FDA is following recommendations from a group of health officials, which includes Dr. Anthony Fauci and Dr.
Francis S. Collins, that said that the data supporting the treatment’s efficacy was not strong enough.Viruses tend to leave survivors with neutralizing antibodies, which can help a previously infected person resist future infection.Since COVID-19 is caused by the novel coronavirus, there isn’t enough data yet to know how much protection the antibodies provide the survivor, according to health officials.While the pharmaceutical industry races to develop a treatment and vaccine, numerous studies have looked into if giving plasma from a COVID-19 survivor to an infected patient could serve as an effective.